骨粗鬆症の薬の使いかたと治療の続けかた

出版社: 羊土社
著者:
発行日: 2023-11-05
分野: 臨床医学:内科  >  老人医学
ISBN: 9784758123594
電子書籍版: 2023-11-05 (第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

商品紹介

かかりつけ医の強みを生かして,患者さんに合わせた骨粗鬆症の診断・予防・治療を行うための必読書!高齢者の転倒・骨折を予防するための治療薬,食事療法,運動療法を網羅!

目次

  • 第1章 骨粗鬆症の治療の始めかた ~誰に始めるか・いつ始めるか
    1 骨粗鬆症のリスク因子とその評価
    2 骨粗鬆症の定義・診断基準
    3 骨密度測定
    4 骨代謝マーカー測定の意義
    5 骨粗鬆症性(脆弱性)骨折の診断・評価
    6 骨粗鬆症の診断において鑑別すべき疾患
    7 骨粗鬆症薬物治療の開始基準

    第2章 骨粗鬆症治療薬の選びかた・使いかた
    1 骨粗鬆症診療の現状
    2 骨粗鬆症薬物療法の第一選択薬の考えかた
    3 カルシウム製剤
    4 活性型ビタミンD3製剤
    5 ビスホスホネート(BP)製剤
    6 選択的エストロゲン受容体モジュレーター(SERM)
    7 副甲状腺ホルモン(PTH)製剤
    8 RANKL阻害薬
    9 ロモソズマブ

    第3章 骨粗鬆症治療薬の切替の判断 ~患者さんに合わせた治療
    1 薬物療法開始後の経過における注意点と治療評価
    2 治療効果不十分と判断する場合と切り替えのタイミング
    3 副甲状腺ホルモン(PTH)製剤からの切り替え,逐次療法
    4 ロモソズマブからの切り替え,逐次療法
    5 RANKL阻害薬(デノスマブ)からの切り替え,逐次療法

    第4章 骨粗鬆症と合併症 ~注意すべきリスクとその管理
    1 カルシウム製剤,活性型ビタミンD3製剤,PTH製剤における高カルシウム血症のリスクとその管理
    2 ビスホスホネート(BP)製剤における顎骨壊死のリスクとその管理
    3 エストロゲン製剤やSERMにおけるリスクとその管理
    4 RANKL阻害薬を用いた際の有効性,有害事象のリスクとその管理
      ~ステロイド性骨粗鬆症を含めた骨粗鬆症における栄養・運動・薬物療法とわれわれの取り組み

    第5章 骨粗鬆症に対する薬以外の治療と骨折予防
    1 骨粗鬆症における運動療法の意義と注意点
    2 骨粗鬆症における食事療法の意義と注意点
    3 転倒と骨折
    4 転倒予防の方法
    5 サルコペニアと筋骨連関
    6 骨粗鬆症検診

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 骨粗鬆症の治療の始めかた~誰に始めるか・いつ始めるか

P.19 掲載の参考文献
1) Darling AL, et al:Dietary protein and bone health:towards a synthesised view. Proc Nutr Soc, 80:165-172, 2021[PMID:33183359]
2) Cauley JA:Estrogen and bone health in men and women. Steroids, 99:11-15, 2015[PMID:25555470]
3) Ravn P, et al:Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res, 14:1622-1627, 1999[PMID:10469292]
4) Asomaning K, et al:The association between body mass index and osteoporosis in patients referred for a bone mineral density examination. J Womens Health (Larchmt), 15:1028-1034, 2006[PMID:17125421]
5) Dargent-Molina P, et al:In elderly women weight is the best predictor of a very low bone mineral density:evidence from the EPIDOS study. Osteoporos Int, 11:881-888, 2000[PMID:11199193]
6) Michaelsson K, et al:Screening for osteopenia and osteoporosis:selection by body composition. Osteoporos Int, 6:120-126, 1996[PMID:8704349]
7) Sukumar D, et al:Obesity alters cortical and trabecular bone density and geometry in women. Osteoporos Int, 22:635-645, 2011[PMID:20533027]
8) Fang J, et al:Multiscale experimental study on the effects of different weight-bearing levels during moderate treadmill exercise on bone quality in growing female rats. Biomed Eng Online, 18:33, 2019[PMID:30902108]
9) Klotzbuecher CM, et al:Patients with prior fractures have an increased risk of future fractures:a summary of the literature and statistical synthesis. J Bone Miner Res, 15:721-739, 2000[PMID:10780864]
10) Kadowaki E, et al:Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women:the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int, 21:1513-1522, 2010[PMID:19924494]
11) Hagino H, et al:The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int, 90:14-21, 2012[PMID:22076525]
12) Ralston SH:Genetics of osteoporosis. Proc Nutr Soc, 66:158-165, 2007[PMID:17466098]
13) Kanis JA, et al:A family history of fracture and fracture risk:a meta-analysis. Bone, 35:1029-1037, 2004[PMID:15542027]
14) Kanis JA, et al:Smoking and fracture risk:a meta-analysis. Osteoporos Int, 16:155-162, 2005[PMID:15175845]
15) Xu Y, et al:Smoking and fracture risk in men:a meta-analysis of cohort studies, using both frequentist and Bayesian approaches. Sci Rep, 12:9270, 2022[PMID:35661791]
16) Kanis JA, et al:Alcohol intake as a risk factor for fracture. Osteoporos Int, 16:737-742, 2005[PMID:15455194]
17) Gregg EW, et al:Physical activity, falls, and fractures among older adults:a review of the epidemiologic evidence. J Am Geriatr Soc, 48:883-893, 2000[PMID:10968291]
18) Joakimsen RM, et al:Physical activity and predisposition for hip fractures:a review. Osteoporos Int, 7:503-513, 1997[PMID:9604045]
19) Etherington J, et al:The effect of weight-bearing exercise on bone mineral density:a study of female ex-elite athletes and the general population. J Bone Miner Res, 11:1333-1338, 1996[PMID:8864908]
20) Howe TE, et al:Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev:CD000333, 2011[PMID:21735380]
21) Nguyen TV, et al:Osteoporosis in elderly men and women:effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res, 15:322-331, 2000[PMID:10703935]
22) Shea B, et al:Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev, 23:552-559, 2002[PMID:12202470]
23) Eysteinsdottir T, et al:Milk consumption throughout life and bone mineral content and density in elderly men and women. Osteoporos Int, 25:663-672, 2014[PMID:23948877]
24) Sato Y, et al:Greater milk intake is associated with lower bone turnover, higher bone density, and higher bone microarchitecture index in a population of elderly Japanese men with relatively low dietary calcium intake:Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int, 26:1585-1594, 2015[PMID:25627112]
25) Kojima A, et al:Association between Dairy Product intake and Risk of Osteoporotic Fractures in Postmenopausal Japanese Women:Secondary Analysis of 15-Year Follow-Up data from the Japanese Population-Based Osteoporosis (JPOS) Cohort Study. J Nutr Health Aging, 27:228-237, 2023[PMID:36973932]
26) Goncerz G, et al:Higher milk consumption is not associated with fracture risk reduction:systematic review and meta-analysis. Folia Med Cracov, 62:137-153, 2022[PMID:36854093]
27) Lips P & van Schoor NM:The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab, 25:585-591, 2011[PMID:21872800]
28) Holick MF:The vitamin D deficiency pandemic:Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord, 18:153-165, 2017[PMID:28516265]
29) 日本内分泌学会, 他:ビタミンD不足・欠乏の判定指針. 日本内分泌学会雑誌, 93:1-10, 2017
30) Wang D & Yang Y:The Relationship Between Serum 25-Hydroxyvitamin D Levels and Osteoporosis in Postmenopausal Women. Clin Interv Aging, 18:619-627, 2023[PMID:37096217]
31) Reid IR:Vitamin D Effect on Bone Mineral Density and Fractures. Endocrinol Metab Clin North Am, 46:935-945, 2017[PMID:29080644]
32) Svejme O, et al:Early menopause and risk of osteoporosis, fracture and mortality:a 34-year prospective observational study in 390 women. BJOG, 119:810-816, 2012[PMID:22531019]
33) Pepe J, et al:Osteoporosis in Premenopausal Women:A Clinical Narrative Review by the ECTS and the IOF. J Clin Endocrinol Metab, 105:dgaa306, 2020[PMID:32453819]
34) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
35) Kanis JA, et al:A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 19:893-899, 2004[PMID:15125788]
36) van Staa TP, et al:The epidemiology of corticosteroid-induced osteoporosis:a meta-analysis. Osteoporos Int, 13:777-787, 2002[PMID:12378366]
37) FRAX(R) 骨折リスク評価ツール https://frax.shef.ac.uk/FRAX/tool.aspx?lang=jp
P.26 掲載の参考文献
1) [The Parathyroid Glands and Metabolic Bone Disease](Albright F, et al, ed), Williams & Wilkins, 1984
2) Consensus development conference:prophylaxis and treatment of osteoporosis. Am J Med, 90:107-110, 1991[PMID:1986575]
3) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser, 843:1-129, 1994[PMID:7941614]
4) 折茂 肇, 他:原発性骨粗鬆症の診断基準.日本骨代謝学会雑誌, 13:113-118, 1995
5) 日本骨代謝学会骨粗鬆症診断基準検討委員会:原発性骨粗鬆症の診断基準(1996年度改訂版) http://jsbmr.umin.jp/guide/pdf/shindan1996.pdf
6) 日本骨代謝学会, 日本骨粗鬆症学会合同原発性骨粗鬆症診断基準改訂検討委員会:原発性骨粗鬆症の診断基準(2012年度改訂版). Osteoporosis Japan, 21:9-21, 2013 http://jsbmr.umin.jp/guide/pdf/g-guideline.pdf
7) Soen S, et al:J Bone Miner Metab, 31:247-257, 2013
8) Klotzbuecher CM, et al:Patients with prior fractures have an increased risk of future fractures:a summary of the literature and statistical synthesis. J Bone Miner Res, 15:721-739, 2000[PMID:10780864]
9) Kanis JA, et al:A meta-analysis of previous fracture and subsequent fracture risk. Bone, 35:375-382, 2004[PMID:15268886]
10) Fujiwara S, et al:Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res, 18:1547-1553, 2003[PMID:12929946]
11) Colon-Emeric C, et al:The contribution of hip fracture to risk of subsequent fractures:data from two longitudinal studies. Osteoporos Int, 14:879-883, 2003[PMID:14530910]
12) Ojo F, et al:History of fractures as predictor of subsequent hip and nonhip fractures among older Mexican Americans. J Natl Med Assoc, 99:412-418, 2007[PMID:17444431]
13) Cummings SR, et al:Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med, 332:767-773, 1995[PMID:7862179]
14) Kanis JA, et al:Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int, 12:989-995, 2001[PMID:11846333]
15) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
16) FRAX(R) 骨折リスク評価ツール https://frax.shef.ac.uk/FRAX/tool.aspx?lang=jp
P.34 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015
2) 「フレイル診療ガイド 2018年版」[長寿医療研究開発費事業(27-23):要介護高齢者, フレイル高齢者, 認知症高齢者に対する栄養療法, 運動療法, 薬物療法に関するガイドライン作成に向けた調査研究班/編], ライフ・サイエンス, 2018
3) Ensrud KE, et al:Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med, 168:382-389, 2008[PMID:18299493]
4) 伊木雅之, 他:骨密度測定から骨折リスク予測に基づく健診へ-その現状と課題-. Osteoporosis Japan, 21:62-66, 2013
5) Solomon DH, et al:Compliance with osteoporosis medications. Arch Intern Med, 165:2414-2419, 2005[PMID:16287772]
6) Gourlay ML, et al:Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med, 366:225-233, 2012[PMID:22256806]
7) de Liefde II, et al:Bone mineral density and fracture risk in type-2 diabetes mellitus:the Rotterdam Study. Osteoporos Int, 16:1713-1720, 2005[PMID:15940395]
8) Oei L, et al:High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control:the Rotterdam Study. Diabetes Care, 36:1619-1628, 2013[PMID:23315602]
P.40 掲載の参考文献
1) Koivula MK, et al:Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem, 45:920-927, 2012[PMID:22480789]
2) Saito M & Marumo K:Collagen cross-links as a determinant of bone quality:a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int, 21:195-214, 2010[PMID:19760059]
3) Shiraki M, et al:Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab, 29:62-70, 2011[PMID:20458602]
4) 「骨粗鬆症診療における骨代謝マーカーの適正使用ガイド 2018年版」(日本骨粗鬆症学会 骨代謝マーカー検討委員会/編), ライフサイエンス出版, 2018
5) Diez-Perez A, et al:International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int, 28:767-774, 2017[PMID:28093634]
6) Chaki O, et al:The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res, 15:1537-1544, 2000[PMID:10934652]
7) Johansson H, et al:A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int, 94:560-567, 2014[PMID:24590144]
P.48 掲載の参考文献
1) Ross PD, et al:Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol, 24:1171-1177, 1995[PMID:8824859]
2) Delmas PD, et al:Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis:four-year results from a randomized clinical trial. J Clin Endocrinol Metab, 87:3609-3617, 2002[PMID:12161484]
3) 森 諭史, 他:椎体骨折評価基準(2012年度改訂版).Osteoporosis Japan, 21:25-32, 2013
4) 森 諭史:腰背痛をどう鑑別するか. 「骨粗鬆症診療実践マニュアル」(松本俊夫 /編), pp216-220, 文光堂, 2003
5) 「大腿骨頚部 転子部骨折診療ガイドライン2021 改訂第3版」(日本整形外科学会, 日本骨折治療学会/監, 日本整形外科学会診療ガイドライン委員会, 大腿骨頚部/転子部骨折診療ガイドライン策定委員会/編), 南江堂, 2021
P.58 掲載の参考文献
1) 田井宣之, 岡崎 亮:骨粗鬆症の診断. 産婦人科治療, 99:455-460, 2009
2) Fukumoto S, et al:Management manual for cancer treatment-induced bone loss (CTIBL):position statement of the JSBMR. J Bone Miner Metab, 38:141-144, 2020[PMID:32020289]
3) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015
4) 「生活習慣病骨折リスクに関する診療ガイド 2019年版」(日本骨粗鬆症学会 生活習慣病における骨折リスク評価委員会/編), ライフサイエンス出版, 2019
P.64 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
2) Fujiwara S, et al:Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res, 18:1547-1553, 2003[PMID:12929946]
3) 「骨粗鬆症の予防と治療ガイドライン 2006年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2006
4) Masunari N, et al:Historical height loss, vertebral deformity, and health-related quality of life in Hiroshima cohort study. Osteoporos Int, 18:1493-1499, 2007[PMID:17541811]
5) Kanis JA, et al:A family history of fracture and fracture risk:a meta-analysis. Bone, 35:1029-1037, 2004[PMID:15542027]
6) 「生活習慣病骨折リスクに関する診療ガイド 2019年版」(日本骨粗鬆症学会生活習慣病における骨折リスク評価委員会/編), ライフサイエンス出版, 2019

第2章 骨粗鬆症治療薬の選びかた・使いかた

P.72 掲載の参考文献
1) Lems WF, et al:Vertebral fracture:epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int, 32:399-411, 2021[PMID:33475820]
2) Gold T, et al:Impact of fractures on quality of life in patients with osteoporosis:a US cross-sectional survey. J Drug Assess, 8:175-183, 2019[PMID:31692954]
3) Cooper C, et al:Population-based study of survival after osteoporotic fractures. Am J Epidemiol, 137:1001-1005, 1993[PMID:8317445]
4) e-Stat:令和4年国民生活基礎調査. https://www.e-stat.go.jp/stat-search/files?page=1&layout=normal&toukei=00450061&tstat=000001206248&metadata=1&data=1
5) Desai RJ, et al:Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures:An Instrumental Variable Analysis. JAMA Netw Open, 1:e180826, 2018[PMID:30646034]
6) Yu F & Xia W:The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos, 14:32, 2019[PMID:30848398]
7) 玉置淳子:骨粗鬆症の基礎知識 骨粗鬆症の疫学. 診断と治療, 108:1123-1128, 2020
8) Nakatoh S, et al:Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis:an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan. Arch Osteoporos, 16:131, 2021[PMID:34515872]
9) Black DM, et al:Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab, 85:4118-4124, 2000[PMID:11095442]
10) Cotte FE & De Pouvourville G:Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res, 11:151, 2011[PMID:21702989]
11) Siris ES, et al:Adherence to bisphosphonate therapy and fracture rates in osteoporotic women:relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc, 81:1013-1022, 2006[PMID:16901023]
12) Kanis JA, et al:Partial adherence:a new perspective on health economic assessment in osteoporosis. Osteoporos Int, 22:2565-2573, 2011[PMID:21617992]
13) 阿部大介, 他:わが国における閉経後女性の骨粗鬆症に対する意識・実態に関するWebアンケート調査. 日本骨粗鬆症学会雑誌, 5:267-276, 2019
14) MS&AD 研究所株式会社:高齢者運転事故と防止対策. 2017 https://prtimes.jp/a/?f=d23104-20170302-7067.pdf
15) Mitchell PJ:Fracture Liaison Services:the UK experience. Osteoporos Int, 22 Suppl 3:487-494, 2011[PMID:21847771]
16) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
17) Nakatoh S, et al:Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture:analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Arch Osteoporos, 16:130, 2021[PMID:34510296]
18) Akesson K, et al:Capture the Fracture:a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int, 24:2135-2152, 2013[PMID:23589162]
19) 遠藤直人, 他:日本骨粗鬆症学会からのお知らせ. 日本骨粗鬆症学会雑誌, 6:289-290, 2020
20) 日本骨粗鬆症学会, 日本脆弱性骨折ネットワーク:日本版 二次骨折予防のための骨折リエゾンサービス(FLS)クリニカルスタンダード. 2020 http://www.josteo.com/ja/news/doc/200518_3.pdf
P.80 掲載の参考文献
1) Tamaki J, et al:Total 25-hydroxyvitamin D levels predict fracture risk:results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int, 28:1903-1913, 2017[PMID:28243705]
2) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
3) Black DM, et al:Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 356:1809-1822, 2007[PMID:17476007]
4) Cosman F, et al:Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med, 375:1532-1543, 2016[PMID:27641143]
5) Saag KG, et al:Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med, 377:1417-1427, 2017[PMID:28892457]
6) Miller PD, et al:Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis:A Randomized Clinical Trial. JAMA, 316:722-733, 2016[PMID:27533157]
7) Cummings SR, et al:Goal-Directed Treatment for Osteoporosis:A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res, 32:3-10, 2017[PMID:27864889]
8) McClung MR, et al:Observations following discontinuation of long-term denosumab therapy. Osteoporos Int, 28:1723-1732, 2017[PMID:28144701]
9) Tsourdi E, et al:Fracture risk and management of discontinuation of denosumab therapy:a systematic review and position statement by ECTS. J Clin Endocrinol Metab, 26:dgaa756, 2020[PMID:33103722]
10) Jamal SA, et al:Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res, 26:1829-1835, 2011[PMID:21491487]
P.87 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015
2) Tang BM, et al:Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older:a meta-analysis. Lancet, 370:657-666, 2007[PMID:17720017]
3) Avenell A, et al:Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev, 2014:CD000227, 2014[PMID:24729336]
4) Kahwati LC, et al:Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults:Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 319:1600-1612, 2018[PMID:29677308]
5) Iuliano S, et al:Effect of dietary sources of calcium and protein on hip fractures and falls in older adults in residential care:cluster randomised controlled trial. BMJ, 375:n2364, 2021[PMID:34670754]
6) 厚生労働省:令和元年国民栄養・健康調査. https://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html
7) Lips P, et al:Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf), 73:277-285, 2010[PMID:20796001]
8) [Dietary Reference Intakes for Calcium and Vitamin D](Ross AC, et al, eds), National Academies Press, 2011
9) Bolland MJ, et al:Effect of calcium supplements on risk of myocardial infarction and cardiovascular events:meta-analysis. BMJ, 341:c3691, 2010[PMID:20671013]
10) Bolland MJ, et al:Calcium supplements with or without vitamin D and risk of cardiovascular events:reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ, 342:d2040, 2011[PMID:21505219]
11) Lewis JR, et al:The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women:a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res, 30:165-175, 2015[PMID:25042841]
P.93 掲載の参考文献
1) Okazaki R, et al:Assessment criteria for vitamin D deficiency/insufficiency in Japan:proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. J Bone Miner Metab, 35:1-5, 2017[PMID:27882481]
2) Holick MF, et al:Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab, 97:1153-1158, 2012[PMID:22442274]
3) Nakamura K, et al:Impact of demographic, environmental, and lifestyle factors on vitamin D sufficiency in 9084 Japanese adults. Bone, 74:10-17, 2015[PMID:25576673]
4) Akter S, et al:Serum 25-hydroxyvitamin D and metabolic syndrome in a Japanese working population:The Furukawa Nutrition and Health Study. Nutrition, 36:26-32, 2017[PMID:28336104]
5) Nakamura K, et al:Vitamin D status, bone mass, and bone metabolism in home-dwelling postmenopausal Japanese women:Yokogoshi Study. Bone, 42:271-277, 2008[PMID:18006400]
6) Sakuma M, et al:Serum 25-hydroxyvitamin D status in hip and spine-fracture patients in Japan. J Orthop Sci, 16:418-423, 2011[PMID:21594670]
7) Nakamura K, et al:Vitamin D sufficiency is associated with low incidence of limb and vertebral fractures in community-dwelling elderly Japanese women:the Muramatsu Study. Osteoporos Int, 22:97-103, 2011[PMID:20333358]
8) Tanaka S, et al:Serum 25-hydroxyvitamin D below 25 ng/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women. J Bone Miner Metab, 32:514-523, 2014[PMID:24061541]
9) Matsumoto T & Endo I:Eldecalcitol for the treatment of osteoporosis. Drugs Today (Barc), 48:189-196, 2012[PMID:22462038]
10) Shikari M, et al:Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture:a placebo-controlled, double-blind prospective study. Endocr J, 43:211-220, 1996[PMID:9026268]
11) Gallagher JC, et al:Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab, 86:3618-3628, 2001[PMID:11502787]
12) Papadimitropoulos E, et al:Meta-analyses of therapies for postmenopausal osteoporosis. VIII:Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev, 23:560-569, 2002[PMID:12202471]
13) Bischoff-Ferrari HA, et al:Prevention of nonvertebral fractures with oral vitamin D and dose dependency:a meta-analysis of randomized controlled trials. Arch Intern Med, 169:551-561, 2009[PMID:19307517]
14) Orimo H, et al:Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture:the Japanese Osteoporosis Intervention Trial (JOINT)-02. Curr Med Res Opin, 27:1273-1284, 2011[PMID:21554143]
15) Schacht E, et al:Combined therapies in osteoporosis:bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neuronal Interact, 7:174-184, 2007[PMID:17627088]
16) Frediani B, et al:Alendronate plus calcitriol:acombined treatment in corticosteroid induced osteoporosis. Osteoporos Int, 9:S10-S11, 1999
17) Nakamura T, et al:Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. J Bone Miner Metab, 31:417-422, 2013[PMID:23575909]
18) Gerdhem P, et al:Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int, 16:1425-1431, 2005[PMID:15744449]
19) Beaudart C, et al:The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power:a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab, 99:4336-4345, 2014[PMID:25033068]
20) O'Donnell S, et al:Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab, 26:531-542, 2008[PMID:18979152]
21) Bischoff-Ferrari HA, et al:Fall prevention with supplemental and active forms of vitamin D:a meta-analysis of randomised controlled trials. BMJ, 339:b3692, 2009[PMID:19797342]
22) Iwamoto J & Sato Y:Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates. Ther Clin Risk Manag, 10:51-59, 2014[PMID:24476669]
23) Saito K, et al:Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis:an open-label randomized controlled study. J Bone Miner Metab, 34:547-554, 2016[PMID:26209166]
24) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
25) 「ステロイド性骨粗鬆症の管理と治療ガイドライン 2014年改訂版」(日本骨代謝学会 ステロイド性骨粗鬆症の管理と治療ガイドライン改訂委員会/編), 大阪大学出版会, 2014 http://jsbmr.umin.jp/guide/pdf/gioguideline.pdf
P.103 掲載の参考文献
1) 井上玲子, 井上大輔:ビスホスホネート. 薬局, 71:3278-3282, 2020
2) Cremers S, et al:Pharmacology of bisphosphonates. Br J Clin Pharmacol, 85:1052-1062, 2019[PMID:30650219]
3) Bone HG, et al:Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 350:1189-1199, 2004[PMID:15028823]
4) Black DM, et al:Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension (FLEX):a randomized trial. JAMA, 296:2927-2938, 2006[PMID:17190893]
5) Black DM, et al:The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis:a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res, 27:243-254, 2012[PMID:22161728]
6) Black DM, et al:Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 356:1809-1822, 2007[PMID:17476007]
7) Black DM, et al:The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis:a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res, 30:934-944, 2015[PMID:25545380]
8) Ebetino FH, et al:The relationship between the chemistry and biological activity of the bisphosphonates. Bone, 49:20-33, 2011[PMID:21497677]
9) Mellstrom DD, et al:Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int, 75:462-468, 2004[PMID:15455188]
10) Kishimoto H, et al:Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis:a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab, 24:405-413, 2006[PMID:16937274]
11) Hagino H, et al:Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis:a comparison with a 2.5mg once-daily dosage regimen. Bone, 59:44-52, 2014[PMID:24184313]
12) Stakkestad JA, et al:Monthly oral ibandronate is effective and well tolerated after 3 years:the MOBILE long-term extension. Clin Rheumatol, 27:955-960, 2008[PMID:18180976]
13) Hagino H, et al:Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab, 30:439-446, 2012[PMID:22134624]
14) Wells GA, et al:Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev:CD001155, 2008[PMID:18253985]
15) Wells G, et al:Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev:CD004523, 2008[PMID:18254053]
16) Matsumoto T, et al:Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis:a randomized placebo-controlled double-blind study. Osteoporos Int, 20:1429-1437, 2009[PMID:19101754]
17) Chesnut CH 3rd, et al:Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 19:1241-1249, 2004[PMID:15231010]
18) Hagino H, et al:A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone, 44:1078-1084, 2009[PMID:19264155]
19) Carmel AS, et al:The 25(OH)D level needed to maintain a favorable bisphosphonate response is >- 33 ng/ml. Osteoporos Int, 23:2479-2487, 2012[PMID:22237813]
20) Okazaki R, et al:Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis. J Bone Miner Metab, 37:185-197, 2019[PMID:29737412]
P.110 掲載の参考文献
1) Taylor HS:Designing the ideal selective estrogen receptor modulator--an achievable goal? Menopause, 16:609-615, 2009[PMID:19182697]
2) Ettinger B, et al:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 282:637-645, 1999[PMID:10517716]
3) Cadarette SM, et al:Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med, 148:637-646, 2008[PMID:18458276]
4) Silverman SL, et al:Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis:results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res, 23:1923-1934, 2008[PMID:18665787]
5) Kaufman JM, et al:An evaluation of the Fracture Risk Assessment Tool (FRAX(R)) as an indicator of treatment efficacy:the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX(R). Osteoporos Int, 24:2561-2569, 2013[PMID:23595562]
P.118 掲載の参考文献
1) Berkeley WN & Beebe SP:A Contribution to the Physiology and Chemistry of the Parathyroid Gland. J Med Res, 20:149-173, 1909[PMID:19971884]
2) Collip JB:The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem, 63:395-438, 1925
3) Collip JB & Leitch DB:A Case of Tetany treated with Parathyrin. Can Med Assoc J, 15:59-60, 1925[PMID:20315252]
4) Greenwald I:The effect of parathyroidectomy upon metabolism. Am J Physiol, 28:103-132, 1911
5) Jahan I & Pitts RF:Effect of parathyroid on renal tubular reabsorption of phosphate and calcium. Am J Physiol, 155:42-49, 1948[PMID:18102666]
6) Barnicot NA:The local action of the parathyroid and other tissues on bone in intracerebral grafts. J Anat, 82:233-248, 1948[PMID:18113751]
7) Niall HD, et al:The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci USA, 71:384-388, 1974[PMID:4521809]
8) Reeve J, et al:Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis:a multicentre trial. Br Med J, 280:1340-1344, 1980[PMID:6992932]
9) 井上旬二:1-34h PTH少量 長期投与におけるビーグル犬の組織学的骨動態分析. 日本整形外科学会雑誌, 59:409-427, 1985
10) Isogai Y, et al:Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res, 11:1384-1393, 1996[PMID:8889836]
11) Dempster DW, et al:Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. J Bone Miner Res, 35:1282-1288, 2020[PMID:32163613]
12) Bouxsein ML, et al:Change in Bone Density and Reduction in Fracture Risk:A Meta-Regression of Published Trials. J Bone Miner Res, 34:632-642, 2019[PMID:30674078]
13) Genant HK, et al:Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res, 8:1137-1148, 1993[PMID:8237484]
14) 日本骨代謝学会, 日本骨粗鬆症学会合同原発性骨粗鬆症診断基準改訂検討委員会:原発性骨粗鬆症の診断基準(2012年度改訂版). 日本骨粗鬆症学会雑誌, 21:9-21, 2013 http://jsbmr.umin.jp/guide/pdf/g-guideline.pdf
15) Neer RM, et al:Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 344:1434-1441, 2001[PMID:11346808]
16) Nakamura T, et al:Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab, 97:3097-3106, 2012[PMID:22723322]
17) Kendler DL, et al:Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO):a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 391:230-240, 2018[PMID:29129436]
18) Geusens P, et al:Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis:The VERO Trial. J Bone Miner Res, 33:783-794, 2018[PMID:29329484]
19) Miller PD, et al:Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis:A Randomized Clinical Trial. JAMA, 316:722-733, 2016[PMID:27533157]
20) Mori S, et al:Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture:final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int, 34:189-199, 2023[PMID:36239756]
21) Bone HG, et al:ACTIVExtend:24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab, 103:2949-2957, 2018[PMID:29800372]
P.125 掲載の参考文献
1) Yasuda H, et al:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95:3597-3602, 1998[PMID:9520411]
2) Lacey DL, et al:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93:165-176, 1998[PMID:9568710]
3) Yasuda H:RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop, 4:207-217, 2013[PMID:24147256]
4) Takahashi N, et al:A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun, 256:449-455, 1999[PMID:10080918]
5) Feng X & Teitelbaum SL:Osteoclasts:New Insights. Bone Res, 1:11-26, 2013[PMID:26273491]
6) Lacey DL, et al:Bench to bedside:elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov, 11:401-419, 2012[PMID:22543469]
7) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
8) 「ステロイド性骨粗鬆症の管理と治療ガイドライン 2014年改訂版」(日本骨代謝学会 ステロイド性骨粗鬆症の管理と治療ガイドライン改訂委員会/編), 大阪大学出版会, 2014 http://jsbmr.umin.jp/guide/pdf/gioguideline.pdf
9) Cummings SR, et al:Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 361:756-765, 2009[PMID:19671655]
10) Bone HG, et al:10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol, 5:513-523, 2017[PMID:28546097]
11) 「生活習慣病骨折リスクに関する診療ガイド 2019年版」(日本骨粗鬆症学会 生活習慣病における骨折リスク評価委員会/編), ライフサイエンス出版, 2019
12) Tanaka S, et al:Safety and Efficacy of Long-term Denosumab Treatment in Japanese Patients with Osteoporosis in Daily Clinical Practice:An Interim Analysis of a Post-marketing Surveillance Study. Therapeutic Research, 39:453-465, 2018
13) Freemantle N, et al:Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study:a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int, 23:317-326, 2012[PMID:21927922]
14) Anastasilakis AD, et al:Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation:Systematic Review and Additional Cases. J Bone Miner Res, 32:1291-1296, 2017[PMID:28240371]
15) Bone HG, et al:Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab, 93:2149-2157, 2008[PMID:18381571]
16) Nakamura T, et al:Clinical Trials Express:fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis:denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab, 99:2599-2607, 2014[PMID:24646104]
17) Kendler DL, et al:Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res, 25:72-81, 2010[PMID:19594293]
P.133 掲載の参考文献
1) Dempster DW, et al:Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. J Bone Miner Res, 35:1282-1288, 2020[PMID:32163613]
2) Soen S, et al:Diagnostic criteria for primary osteoporosis:year 2012 revision. J Bone Miner Metab, 31:247-257, 2013[PMID:23553500]
3) Saag KG, et al:Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med, 377:1417-1427, 2017[PMID:28892457]
4) Kendler DL, et al:Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO):a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 391:230-240, 2018[PMID:29129436]
5) Hagino H, et al:A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture:primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int, 32:2301-2311, 2021[PMID:34002252]
6) 日本病院会:使用薬剤の薬価(薬価基準)の一部改正等について. 保医発 0225第9号, 2019 https://www.hospital.or.jp/pdf/14_20190225_02.pdf
7) Kashii M, et al:Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int, 34:563-572, 2023[PMID:36585509]
8) McClung MR, et al:The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med, 134:541-551, 2022[PMID:35635798]
9) Cosman F, et al:Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med, 375:1532-1543, 2016[PMID:27641143]
10) Lewiecki EM, et al:One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions:Results of the FRAME Extension Study. J Bone Miner Res, 34:419-428, 2019[PMID:30508316]
11) Miyauchi A, et al:Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos, 14:59, 2019[PMID:31168657]
12) Miyauchi A, et al:Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab, 39:278-288, 2021[PMID:33057807]
13) Black DM, et al:Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 348:1535-1541, 1996[PMID:8950879]
14) McClung MR, et al:Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 344:333-340, 2001[PMID:11172164]
15) Black DM, et al:Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 356:1809-1822, 2007[PMID:17476007]
16) Cummings SR, et al:Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 361:756-765, 2009[PMID:19671655]
17) Langdahl BL, et al:Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy:a randomised, open-label, phase 3 trial. Lancet, 390:1585-1594, 2017[PMID:28755782]
18) Takada J, et al:Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide:a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab, 38:310-315, 2020[PMID:31707465]
19) Schemitsch EH, et al:A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures. J Bone Joint Surg Am, 102:693-702, 2020[PMID:31977817]
20) Bhandari M, et al:Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture:A Randomized Phase-2 Study. J Bone Joint Surg Am, 102:1416-1426, 2020[PMID:32358413]
21) McClung MR, et al:A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int, 31:2231-2241, 2020[PMID:32623487]

第3章 骨粗鬆症治療薬の切替の判断~患者さんに合わせた治療

P.141 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
2) Fontalis A & Eastell R:The challenge of long-term adherence:The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone, 136:115336, 2020[PMID:32234415]
3) Leslie WD, et al:Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Osteoporos Int, 30:1445-1453, 2019[PMID:31016351]
4) Diez-Perez A, et al:Treatment failure in osteoporosis. Osteoporos Int, 23:2769-2774, 2012[PMID:22836278]
5) 「骨粗鬆症診療における骨代謝マーカーの適正使用ガイド 2018年版」(日本骨粗鬆症学会 骨代謝マーカー検討委員会/編), ライフサイエンス出版, 2018
6) 「骨代謝マーカーハンドブック」(日本骨粗鬆症学会 骨代謝マーカー検討委員会/編), メディカルレビュー社, 2022
7) Sarkar S, et al:Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res, 17:1-10, 2002[PMID:11771654]
8) Tsujimoto M, et al:PINP as an aid for monitoring patients treated with teriparatide. Bone, 48:798-803, 2011[PMID:21168536]
9) Cosman F, et al:T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. J Bone Miner Res, 35:1333-1342, 2020[PMID:32445228]
10) Cummings SR, et al:Goal-Directed Treatment for Osteoporosis:A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res, 32:3-10, 2017[PMID:27864889]
11) Black DM, et al:Atypical Femur Fractures:Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. Endocr Rev, 40:333-368, 2019[PMID:30169557]
12) Adler RA, et al:Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment:Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res, 31:16-35, 2016[PMID:26350171]
13) Black DM, et al:Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med, 383:743-753, 2020[PMID:32813950]
P.144 掲載の参考文献
1) Cummings SR, et al:Goal-Directed Treatment for Osteoporosis:A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res, 32:3-10, 2017[PMID:27864889]
2) Black DM, et al:Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction:meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol, 8:672-682, 2020[PMID:32707115]
3) Bouxsein ML, et al:Change in Bone Density and Reduction in Fracture Risk:A Meta-Regression of Published Trials. J Bone Miner Res, 34:632-642, 2019[PMID:30674078]
4) Lorentzon M:Treating osteoporosis to prevent fractures:current concepts and future developments. J Intern Med, 285:381-394, 2019[PMID:30657216]
5) Ominsky MS, et al:Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab. J Bone Miner Res, 30:1280-1289, 2015[PMID:25684625]
6) Diez-Perez A, et al:Treatment failure in osteoporosis. Osteoporos Int, 23:2769-2774, 2012[PMID:22836278]
7) Black DM, et al:Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med, 366:2051-2053, 2012[PMID:22571169]
8) Ebina K, et al:Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab, 36:478-487, 2018[PMID:28766140]
9) Ebina K, et al:Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int, 33:1807-1813, 2022[PMID:35362725]
10) Ebina K, et al:Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol, 31:485-492, 2021[PMID:32412351]
11) Leder BZ, et al:Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study):extension of a randomised controlled trial. Lancet, 386:1147-1155, 2015[PMID:26144908]
12) Ebina K, et al:The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab, 35:91-98, 2017[PMID:26762133]
P.150 掲載の参考文献
1) Marcus R, et al:The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res, 18:18-23, 2003[PMID:12510801]
2) Shiraki M, et al:Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures:rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). J Bone Miner Metab, 29:37-43, 2011[PMID:20461422]
3) Gallagher JC, et al:Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab, 90:1583-1587, 2005[PMID:15613428]
4) Kanis JA, et al:A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 19:893-899, 2004[PMID:15125788]
5) Sin DD, et al:The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med, 114:10-14, 2003[PMID:12543283]
6) Schwartz AV, et al:Older women with diabetes have an increased risk of fracture:a prospective study. J Clin Endocrinol Metab, 86:32-38, 2001[PMID:11231974]
7) Ensrud KE, et al:Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med, 167:133-139, 2007[PMID:17242313]
8) Miyauchi A, et al:Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study:12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone, 47:493-502, 2010[PMID:20580870]
9) Nakamura T, et al:Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab, 97:3097-3106, 2012[PMID:22723322]
10) Sugimoto T, et al:Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients:the TWICE study. Osteoporos Int, 30:2321-2331, 2019[PMID:31392401]
11) Miller PD, et al:Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis:A Randomized Clinical Trial. JAMA, 316:722-733, 2016[PMID:27533157]
12) Liu J, et al:Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries. J Bone Miner Res, 36:2309-2316, 2021[PMID:34490946]
13) Usui T, et al:Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world:a claims database analysis. Arch Osteoporos, 13:54, 2018[PMID:29725863]
14) Black DM, et al:One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 353:555-565, 2005[PMID:16093464]
15) Sugimoto T, et al:Vertebral fracture risk after once-weekly teriparatide injections:follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin, 29:195-203, 2013[PMID:23259702]
16) Lippuner K:The future of osteoporosis treatment-a research update. Swiss Med Wkly, 142:w13624, 2012[PMID:22815185]
17) Ettinger B, et al:Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res, 19:745-751, 2004[PMID:15068497]
18) Jakob F, et al:Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates:36-month results from the European Forsteo Observational Study. Eur J Endocrinol, 166:87-97, 2012[PMID:22048967]
19) Eastell R, et al:Sequential treatment of severe postmenopausal osteoporosis after teriparatide:final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res, 24:726-736, 2009[PMID:19049337]
20) Lyritis G, et al:Back pain during different sequential treatment regimens of teriparatide:results from EUROFORS. Curr Med Res Opin, 26:1799-1807, 2010[PMID:20482322]
21) Miyaoka D, et al:Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis. Calcif Tissue Int, 101:396-403, 2017[PMID:28589205]
22) Ebina K, et al:The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab, 35:91-98, 2017[PMID:26762133]
23) Niimi R, et al:Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab:A Prospective, Randomized, Open-Label Trial. JBMR Plus, 2:289-294, 2018[PMID:30283910]
24) Kocjan T, et al:Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis. Endocr Pract, 27:941-947, 2021[PMID:34111556]
25) Shane E, et al:Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. J Clin Endocrinol Metab, 107:e1528-e1540, 2022[PMID:34849989]
26) Miyagi M, et al:The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients. J Orthop Sci, 24:153-158, 2019[PMID:30146385]
27) 村田幸佑, 他:テリパラチド週一製剤からゾレドロン酸への逐次療法の有効性. 日本骨粗鬆症学会雑誌, 7:272, 2021
P.158 掲載の参考文献
1) Cosman F, et al:Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med, 375:1532-1543, 2016[PMID:27641143]
2) Saag KG, et al:Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med, 377:1417-1427, 2017[PMID:28892457]
3) Lewiecki EM, et al:One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions:Results of the FRAME Extension Study. J Bone Miner Res, 34:419-428, 2019[PMID:30508316]
4) 宮内章光:ロモソズマブの安全性に関する注意点は?「新装版 もう悩まない!骨粗鬆症診療」(竹内靖博/編), 日本医事新報社, 2022
5) Cosman F, et al:Romosozumab and antiresorptive treatment:the importance of treatment sequence. Osteoporos Int, 33:1243-1256, 2022[PMID:35165774]
6) Langdahl BL, et al:Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy:a randomised, open-label, phase 3 trial. Lancet, 390:1585-1594, 2017[PMID:28755782]
7) McClung MR, et al:Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density:A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res, 33:1397-1406, 2018[PMID:29694685]
8) Cummings SR, et al:Goal-Directed Treatment for Osteoporosis:A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res, 32:3-10, 2017[PMID:27864889]
9) Cosman F, et al:Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals. JBMR Plus, 5:e10546, 2021[PMID:34761149]
10) Miyauchi A, et al:Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos, 14:59, 2019[PMID:31168657]
11) McClung MR, et al:A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int, 31:2231-2241, 2020[PMID:32623487]
12) Miyauchi A, et al:JOS 2021, October 8-10, 2021, Virtual Meeting
13) Ebina K, et al:Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int, 33:1807-1813, 2022[PMID:35362725]
14) Kobayakawa T, et al:Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy:The prospective VICTOR study. Bone, 162:116480, 2022[PMID:35787482]
15) Cosman F, et al:Multiple Vertebral Fractures After Denosumab Discontinuation:FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. J Bone Miner Res, 37:2112-2120, 2022[PMID:36088628]
16) 使用薬剤の薬価(薬価基準)の一部改正等について. 保医発 0225第9号, 平成31年2月25日
17) イベニティ皮下注 105mgシリンジの保険適用に係る留意事項の一部改正について. 保医発 0913第1号, 令和元年9月13日
18) 宮内章光:新規骨形成促進薬ロモソズマブの安全性.日本骨粗鬆症学会誌, 7:349-356, 2021
19) Lewiecki EM, et al:A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab, 103:3183-3193, 2018[PMID:29931216]
20) Okazaki R, et al:Assessment criteria for vitamin D deficiency/insufficiency in Japan-proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocr J, 64:1-6, 2017[PMID:28003569]
21) 独立行政法人医薬品医療機器総合機構:エルデカルシトールによる高カルシウム血症と血液検査の遵守について. PMDAからの医薬品適正使用のお願い, No 13:2020年10月 https://www.pmda.go.jp/files/000237206.pdf
22) 顎骨壊死検討委員会:薬剤関連顎骨壊死の病態と管理:顎骨壊死検討委員会ポジションペーパー2023. 2023 https://www.jsoms.or.jp/medical/pdf/2023/0217_1.pdf
23) 厚生労働省:新型コロナワクチンQ&A-新型コロナワクチンとそれ以外のワクチンは, 同時に接種することはできますか. https://www.cov19-vaccine.mhlw.go.jp/qa/0037.html(2023年9月20日閲覧)
24) 米国骨代謝学会(ASBMR)Websiteより:Joint Guidance on COVID-19 Vaccination and Osteoporosis Management from the ASBMR, AACE, Endocrine Society, ECTS, IOF, and NOF https://www.asbmr.org/about/statement-detail/joint-guidance-on-covid-19-vaccine-osteoporosis(2023年9月20日閲覧)
P.165 掲載の参考文献
1) Cummings SR, et al:Goal-Directed Treatment for Osteoporosis:A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res, 32:3-10, 2017[PMID:27864889]
2) Bone HG, et al:10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol, 5:513-523, 2017[PMID:28546097]
3) Ha J, et al:Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporos Int, 33:1591-1599, 2022[PMID:35376989]
4) Ebina K, et al:Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol, 31:485-492, 2021[PMID:32412351]
5) Kendler D, et al:Bone Mineral Density After Transitioning From Denosumab to Alendronate. J Clin Endocrinol Metab, 105:e255-e264, 2020[PMID:31665314]
6) Anastasilakis AD, et al:Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res, 34:2220-2228, 2019[PMID:31433518]
7) Solling AS, et al:Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis:A 2-Year Randomized Study. J Bone Miner Res, 36:1245-1254, 2021[PMID:33813753]
8) Makras P, et al:The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone, 138:115478, 2020[PMID:32534221]
9) Laroche M, et al:Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep, 13:100290, 2020[PMID:32715031]
10) Kondo H, et al:Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. J Bone Miner Metab, 38:894-902, 2020[PMID:32656645]
11) Everts-Graber J, et al:A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. J Bone Miner Res, 35:1207-1215, 2020[PMID:31991007]
12) Makras P, et al:The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. J Clin Endocrinol Metab, 106:e4155-e4162, 2021[PMID:33978745]
13) Leder BZ, et al:Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study):extension of a randomised controlled trial. Lancet, 386:1147-1155, 2015[PMID:26144908]
14) Kobayakawa T, et al:Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients:A prospective cohort study. Bone Rep, 14:101068, 2021[PMID:33981812]
15) Ebina K, et al:Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine, 88:105219, 2021[PMID:34020048]
16) Bone HG, et al:Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab, 96:972-980, 2011[PMID:21289258]
17) Anastasilakis AD, et al:Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation:Systematic Review and Additional Cases. J Bone Miner Res, 32:1291-1296, 2017[PMID:28240371]
18) Florez H, et al:Spontaneous vertebral fractures after denosumab discontinuation:A case collection and review of the literature. Semin Arthritis Rheum, 49:197-203, 2019[PMID:30826108]
19) Ferrari S & Langdahl B:Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol, 19:307-317, 2023[PMID:37024711]
20) Kobayakawa T, et al:Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy:The prospective VICTOR study. Bone, 162:116480, 2022[PMID:35787482]
21) Ebina K, et al:Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int, 33:1807-1813, 2022[PMID:35362725]

第4章 骨粗鬆症と合併症~注意すべきリスクとその管理

P.174 掲載の参考文献
1) Obara T & Fujimoto Y:Diagnosis and treatment of patients with parathyroid carcinoma:an update and review. World J Surg, 15:738-744, 1991[PMID:1767540]
2) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
3) 日本透析医学会:慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日本透析医学会雑誌, 45:301-356, 2012
4) Miyauchi A, et al:Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study:12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone, 47:493-502, 2010[PMID:20580870]
5) Hong P, et al:Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res, 18:116, 2023[PMID:36797767]
P.181 掲載の参考文献
1) Ruggiero SL, et al:Osteonecrosis of the jaws associated with the use of bisphosphonates:a review of 63 cases. J Oral Maxillofac Surg, 62:527-534, 2004[PMID:15122554]
2) Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons:American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 65:369-376, 2007[PMID:17307580]
3) 「薬剤関連顎骨壊死の病態と管理:顎骨壊死検討委員会ポジションペーパー2023」(顎骨壊死検討委員会/編), 日本口腔外科学会, 2023 https://www.jsoms.or.jp/medical/pdf/work/guideline_202307.pdf
4) Garcia-Ferrer L, et al:MRI of mandibular osteonecrosis secondary to bisphosphonates. AJR Am J Roentgenol, 190:949-955, 2008[PMID:18356441]
5) 藤盛真樹, 他:ビスホスホネート投与患者の抜歯後 BRONJ発生に関する多施設共同前向き研究. 日本口腔外科学会雑誌, 68:168-183, 2022
6) Kunihara T, et al:Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos Int, 34:1101-1109, 2023[PMID:37002373]
7) Xu S, et al:Associations between osteoporosis and risk of periodontitis:A pooled analysis of observational studies. Oral Dis, 27:357-369, 2021[PMID:32615008]
8) Mucke T, et al:Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid-A prospective study over 6 years. J Craniomaxillofac Surg, 44:1689-1693, 2016[PMID:27555374]
9) Hasegawa T, et al:A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy:can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int, 28:2465-2473, 2017[PMID:28451732]
10) Taguchi A, et al:Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin, 32:1261-1268, 2016[PMID:27007294]
11) Taguchi A, et al:Cooperation between physicians and dentists for osteonecrosis of the jaw:a 2022 Japanese survey. J Bone Miner Metab, 2023 Jul 30. doi:10.1007/s00774-023-01458-3. Online ahead of print. [PMID:37516668]
12) Kamimura M, et al:Long waiting time before tooth extraction may increase delayed wound healing in elderly Japanese. Osteoporos Int, 30:621-628, 2019[PMID:30460382]
P.191 掲載の参考文献
1) 「ホルモン補充療法ガイドライン2017年度版」(日本産科婦人科学会・日本女性医学学会/編・監), 日本産科婦人科学会, 2017
2) Rossouw JE, et al:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288:321-333, 2002[PMID:12117397]
3) Boardman HM, et al:Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 2015:CD002229, 2015[PMID:25754617]
4) Canonico M, et al:Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women:systematic review and meta-analysis. BMJ, 336:1227-1231, 2008[PMID:18495631]
5) Fournier A, et al:Unequal risks for breast cancer associated with different hormone replacement therapies:results from the E3N cohort study. Breast Cancer Res Treat, 107:103-111, 2008[PMID:17333341]
6) Cushman M, et al:Estrogen plus progestin and risk of venous thrombosis. JAMA, 292:1573-1580, 2004[PMID:15467059]
7) Scarabin PY, et al:Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet, 362:428-432, 2003[PMID:12927428]
8) Wassertheil-Smoller S, et al:Effect of estrogen plus progestin on stroke in postmenopausal women:the Women's Health Initiative:a randomized trial. JAMA, 289:2673-2684, 2003[PMID:12771114]
9) de Villiers TJ, et al:Revised Global Consensus Statement on Menopausal Hormone Therapy. Climacteric, 19:313-315, 2016[PMID:27322027]
10) Chlebowski RT, et al:Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. J Natl Compr Canc Netw, 13:917-924, 2015[PMID:26150583]
11) Jaakkola S, et al:Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int J Cancer, 131:E537-E543, 2012[PMID:22024969]
12) Grady D, et al:Hormone replacement therapy and endometrial cancer risk:a meta-analysis. Obstet Gynecol, 85:304-313, 1995[PMID:7824251]
13) Beral V, et al:Menopausal hormone use and ovarian cancer risk:individual participant meta-analysis of 52 epidemiological studies. Lancet, 385:1835-1842, 2015[PMID:25684585]
14) Liu B, et al:Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women:prospective cohort study. BMJ, 337:a386, 2008[PMID:18617493]
15) Wakatsuki A, et al:Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation, 108:808-813, 2003[PMID:12900341]
16) 菖蒲川紀久子, 他:塩酸ラロキシフェン内服中に発症した深部静脈血栓症の1例. Osteoporosis Japan, 15:478-481, ライフサイエンス出版, 2007
17) Ettinger B, et al:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 282:637-645, 1999[PMID:10517716]
18) Iikuni N, et al:Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab, 30:674-682, 2012[PMID:22752125]
19) 日本循環器学会, 他 /編:肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン(2017年改訂版). p69, 2018 https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf
20) Davies GC, et al:Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol, 93:558-565, 1999[PMID:10214833]
21) 日本イーライリリー:エビスタ(R)錠 60mgインタビューフォーム(2019年7月改訂第9版)
22) ファイザー:ビビアント(R)錠 20mgインタビューフォーム(2022年9月改訂第10版)
23) Pinkerton JV, et al:Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens:a randomized, controlled trial. Menopause, 16:1116-1124, 2009[PMID:19546826]
24) Lindsay R, et al:Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril, 92:1045-1052, 2009[PMID:19635616]
25) Lobo RA, et al:Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril, 92:1025-1038, 2009[PMID:19635615]
P.198 掲載の参考文献
1) Prevention and management of osteoporosis. World Health Organ Tech Rep Ser, 921:1-164, back cover, 2003[PMID:15293701]
2) 厚生労働省:日本人の食事摂取基準(2020年版). 2019 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/eiyou/syokuji_kijyun.html
3) 厚生労働省:平成29年国民健康・栄養調査報告. 2018 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/eiyou/h29-houkoku.html
4) Sunyecz JA & Weisman SM:The role of calcium in osteoporosis drug therapy. J Womens Health (Larchmt), 14:180-192, 2005[PMID:15775736]
5) Okazaki R:Update on recent progress in vitamin D research. Vitamin D insufficiency/deficiency. Clin Calcium, 27:1601-1608, 2017[PMID:29074833]
6) Uenishi K: Nutrition and bone health. Present knowledge and practice. Clin Calcium, 19:1028-1031, 2009[PMID:19568001]
7) 「本当に必要な『ゆるスクワット』と『かかと落とし』」(中村幸男/著), pp1-127, 小学館, 2018
8) Yamazaki S, et al:Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Metab, 22:500-508, 2004[PMID:15316873]
9) Howe TE, et al:Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev, 6:CD000333, 2011[PMID:21735380]
10) Nakamura T, et al:Clinical Trials Express:fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis:denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab, 99:2599-2607, 2014[PMID:24646104]
11) Brown JP, et al:Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass:a randomized, blinded, phase 3 trial. J Bone Miner Res, 24:153-161, 2009[PMID:18767928]
12) Cosman F, et al:Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med, 375:1532-1543, 2016[PMID:27641143]
13) Kobayashi T, et al:Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis-Case Series. J Clin Med, 7:479, 2018[PMID:30477250]
14) Nakamura Y, et al:Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res, 5:17021, 2017[PMID:29021920]
15) Suzuki T, et al:Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis. Ther Clin Risk Manag, 14:453-459, 2018[PMID:29535527]
16) Nakamura Y, et al:Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment. Ther Clin Risk Manag, 14:543-549, 2018[PMID:29559791]
17) Saag KG, et al:Denosumab versus risedronate in glucocorticoid-induced osteoporosis:a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol, 6:445-454, 2018[PMID:29631782]
18) Buckley L, et al:2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken), 69:1095-1110, 2017[PMID:28585410]
19) Ishiguro S, et al:The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos, 12:44, 2017[PMID:28425086]
20) Suzuki T, et al:Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol, 28:885-889, 2018[PMID:29251033]
21) Ferrieres L, et al:No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis:a systematic literature review and meta-analysis. Arch Osteoporos, 15:10, 2020[PMID:31897759]
22) Abe I, et al:Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters:Effect of denosumab on glycemic parameters. Medicine (Baltimore), 98:e18067, 2019[PMID:31764838]
23) Fraser TR, et al:The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis:a 'real-life' study. J Endocrinol Invest, 43:469-475, 2020[PMID:31664706]

第5章 骨粗鬆症に対する薬以外の治療と骨折予防

P.208 掲載の参考文献
1) O'Bryan SJ, et al:Progressive Resistance Training for Concomitant Increases in Muscle Strength and Bone Mineral Density in Older Adults:A Systematic Review and Meta-Analysis. Sports Med, 52:1939-1960, 2022[PMID:35608815]
2) Massini DA, et al:The Effect of Resistance Training on Bone Mineral Density in Older Adults:A Systematic Review and Meta-Analysis. Healthcare (Basel), 10:1129, 2022[PMID:35742181]
3) Shojaa M, et al:Effects of dynamic resistance exercise on bone mineral density in postmenopausal women:a systematic review and meta-analysis with special emphasis on exercise parameters. Osteoporos Int, 31:1427-1444, 2020[PMID:32399891]
4) Kemmler W, et al:Effects of Different Types of Exercise on Bone Mineral Density in Postmenopausal Women:A Systematic Review and Meta-analysis. Calcif Tissue Int, 107:409-439, 2020[PMID:32785775]
5) Saquetto MB, et al:Effects of water-based exercises on functioning of postmenopausal women:A systematic review with meta-analysis. Exp Gerontol, 166:111875, 2022[PMID:35764204]
6) Schinzel E, et al:The effect of aquatic exercise on bone mineral density in older adults. A systematic review and meta-analysis. Front Physiol, 14:1135663, 2023[PMID:36994417]
7) Manaye S, et al:The Role of High-intensity and High-impact Exercises in Improving Bone Health in Postmenopausal Women:A Systematic Review. Cureus, 15:e34644, 2023[PMID:36895528]
8) Kitagawa T, et al:A comparison of different exercise intensities for improving bone mineral density in postmenopausal women with osteoporosis:A systematic review and meta-analysis. Bone Rep, 17:101631, 2022[PMID:36310762]
9) de Oliveira RDJ, et al:Effectiveness of whole-body vibration on bone mineral density in postmenopausal women:a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int, 34:29-52, 2023[PMID:36282343]
10) Linhares DG, et al:Effects of Multicomponent Exercise Training on the Health of Older Women with Osteoporosis:A Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 19:14195, 2022[PMID:36361073]
11) Avin KG, et al:Management of falls in community-dwelling older adults:clinical guidance statement from the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. Phys Ther, 95:815-834, 2015[PMID:25573760]
12) Lusardi MM, et al:Determining Risk of Falls in Community Dwelling Older Adults:A Systematic Review and Meta-analysis Using Posttest Probability. J Geriatr Phys Ther, 40:1-36, 2017[PMID:27537070]
13) Maruya K, et al:Effect of a simple and adherent home exercise program on the physical function of community dwelling adults sixty years of age and older with pre-sarcopenia or sarcopenia. J Phys Ther Sci, 28:3183-3188, 2016[PMID:27942146]
14) 石橋英明, 他:地域在住中高年者におけるロコモティブシンドローム対策のための運動介入効果. 日本整形外科学会雑誌, 90:821-828, 2016
15) 新井智之, 他:地域在住中高年者に対するロコモーショントレーニングの転倒予防効果の検討. 「第2回 日本予防理学療法学会学術集会 抄録集」(日本予防理学療法学会/編), p38, 2015
16) 新井智之, 他:高齢者に対する単発のロコモ講習会後の運動継続率:2カ月後と2年後の追跡アンケート調査から. 日本骨粗鬆症学会雑誌, 4:171-176, 2018
17) 新井智之, 他:自治体介護予防事業としてのロコモコールプログラムの運動機能改善効果と6カ月後の検証. 日本骨粗鬆症学会雑誌, 4:531-540, 2018
18) 本郷道生, 他:骨粗鬆症患者に対する背筋運動療法の腰背痛と脊柱湾曲に及ぼす効果. Journal of spine research, 5:901-904, 2014
19) Sinaki M, et al:Stronger back muscles reduce the incidence of vertebral fractures:a prospective 10 year follow-up of postmenopausal women. Bone, 30:836-841, 2002[PMID:12052450]
P.216 掲載の参考文献
1) 厚生労働省:「日本人の食事摂取基準(2020年版)」策定検討会報告書. 2019 https://www.mhlw.go.jp/stf/newpage_08517.html
2) 斎藤 充:骨材質特性の評価法の現状と今後の展望. 日本臨床, 78:2036-2042, 2020
3) 厚生労働省:令和元年国民健康・栄養調査報告. 2019 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/eiyou/r1-houkoku_00002.html
4) Ohta H, et al:Recent nutritional trends of calcium and vitamin D in East Asia. Osteoporos Sarcopenia, 2:208-213, 2016[PMID:30775488]
5) 石井光一, 他/著:簡便な「カルシウム自己チェック表」の開発とその信頼度の確定. 日本骨粗鬆症学会雑誌, 13:497-502, 2005
6) Kanis JA, et al:Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int, 31:1-12, 2020[PMID:31720707]
7) Tamaki J, et al:Total 25-hydroxyvitamin D levels predict fracture risk:results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int, 28:1903-1913, 2017[PMID:28243705]
8) 小林友紀:若年女性におけるビタミンD栄養状態と骨および筋肉との関係. 日本骨粗鬆症学会誌, 6:414-418, 2020
9) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015 http://www.josteo.com/ja/guideline/doc/15_1.pdf
10) 文部科学省:日本食品標準成分表 2020年版(八訂). 2020 https://www.mext.go.jp/a_menu/syokuhinseibun/mext_01110.html
11) 厚生労働省:「食事バランスガイド」について https://www.mhlw.go.jp/bunya/kenkou/eiyou-syokuji.html
P.220 掲載の参考文献
1) 細井孝之:転倒と骨折. 日本老年医学会雑誌, 50:36-39, 2013
2) 日本病院会 QIプロジェクト:平成 29年度医療の質の評価・公表等推進事業結果報告. 2019 https://www.hospital.or.jp/qipro/report/file/1674318564.pdf
3) Robinovitch SN, et al:Prediction of femoral impact forces in falls on the hip. J Biomech Eng, 113:366-374, 1991[PMID:1762432]
4) Hagino H, et al:Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci, 15:737-745, 2010[PMID:21116890]
5) Palvanen M, et al:The injury mechanisms of osteoporotic upper extremity fractures among older adults:a controlled study of 287 consecutive patients and their 108 controls. Osteoporos Int, 11:822-831, 2000[PMID:11199185]
6) Cooper C, et al:Incidence of clinically diagnosed vertebral fractures:a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res, 7:221-227, 1992[PMID:1570766]
7) Yamada T, et al:Influence of the Sagittal Vertical Axis on the Risk of Falls in Community-Dwelling Elderly People:A Retrospective Longitudinal Study. Spine Surg Relat Res, 4:237-241, 2020[PMID:32864490]
P.226 掲載の参考文献
1) 内閣府:令和4年版高齢社会白書(全体版). 2021 https://www8.cao.go.jp/kourei/whitepaper/w-2022/html/zenbun/index.html
2) 厚生労働省:STOP!転倒災害プロジェクト. https://anzeninfo.mhlw.go.jp/information/tentou1501.html
3) Niino N, et al:Frequencies and circumstances of falls in the National Institute for Longevity Sciences, Longitudinal Study of Aging (NILS-LSA). J Epidemiol, 10:S90-S94, 2000[PMID:10835834]
4) Hagino H, et al:Survey of hip fractures in Japan:Recent trends in prevalence and treatment. J Orthop Sci, 22:909-914, 2017[PMID:28728988]
5) Deandrea S, et al:Risk factors for falls in community-dwelling older people:a systematic review and meta-analysis. Epidemiology, 21:658-668, 2010[PMID:20585256]
6) Campbell AJ & Robertson MC:Implementation of multifactorial interventions for fall and fracture prevention. Age Ageing, 35 Suppl 2:ii60-ii64, 2006[PMID:16926208]
7) Montero-Odasso M, et al:World guidelines for falls prevention and management for older adults:a global initiative. Age Ageing, 51:afac205, 2022[PMID:36178003]
8) Kojima T, et al:Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int, 12:425-430, 2012[PMID:22212467]
9) Stubbs B, et al:Pain is associated with recurrent falls in community-dwelling older adults:evidence from a systematic review and meta-analysis. Pain Med, 15:1115-1128, 2014[PMID:24837341]
10) 和田 崇, 他:地域在住高齢者における診断された運動器疾患数と転倒発生の関連についての横断的研究. 日本転倒予防学会誌, 3:37-45, 2017
11) 鳥羽研二, 他:転倒リスク予測のための「転倒スコア」の開発と妥当性の検証. 日本老年医学会雑誌, 42:346-352, 2005
12) Okochi J, et al:Simple screening test for risk of falls in the elderly. Geriatrics & gerontology international, 6:223-227, 2006
13) Shumway-Cook A, et al:Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys Ther, 80:896-903, 2000[PMID:10960937]
14) Buatois S, et al:A simple clinical scale to stratify risk of recurrent falls in community-dwelling adults aged 65 years and older. Phys Ther, 90:550-560, 2010[PMID:20203094]
15) Vellas BJ, et al:One-leg balance is an important predictor of injurious falls in older persons. J Am Geriatr Soc, 45:735-738, 1997[PMID:9180669]
16) Ganz DA & Latham NK:Prevention of Falls in Community-Dwelling Older Adults. N Engl J Med, 382:734-743, 2020[PMID:32074420]
17) Sherrington C, et al:Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev, 1:CD012424, 2019[PMID:30703272]
18) Hayashi T, et al:Differences in Falls between Older Adult Participants in Group Exercise and Those Who Exercise Alone:A Cross-Sectional Study Using Japan Gerontological Evaluation Study (JAGES) Data. Int J Environ Res Public Health, 15:1413, 2018[PMID:29976848]
19) Clemson L, et al:Integration of balance and strength training into daily life activity to reduce rate of falls in older people (the LiFE study):randomised parallel trial. BMJ, 345:e4547, 2012[PMID:22872695]
20) Hopewell S, et al:Multifactorial and multiple component interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev, 7:CD012221, 2018[PMID:30035305]
P.232 掲載の参考文献
1) Rosenberg IH:Summary comments :Epidemiological and methodological problem in determining nutritional status of older persons. Am J Clin Nutr, 50:1231-1233, 1989
2) Cruz-Jentoft AJ, et al:Sarcopenia:European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in Older People. Age Ageing, 39:412-423, 2010[PMID:20392703]
3) Chen LK, et al:Sarcopenia in Asia:consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc, 15:95-101, 2014[PMID:24461239]
4) Cruz-Jentoft AJ, et al:Sarcopenia:revised European consensus on definition and diagnosis. Age Ageing, 48:16-31, 2019[PMID:30312372]
5) Malmstrom TK & Morley JE:SARC-F:a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc, 14:531-532, 2013[PMID:23810110]
6) Chen LK, et al:Asian Working Group for Sarcopenia:2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 21:300-307.e2, 2020(PMID:32033882)
7) Ida S, et al:Development of a Japanese version of the SARC-F for diabetic patients:an examination of reliability and validity. Aging Clin Exp Res, 29:935-942, 2017(PMID:27832470)
8) Yakabe M, et al:Updated concept of sarcopenia based on muscle-bone relationship. J Bone Miner Metab, 38:7-13, 2020(PMID:31583540)
9) Hosoi T, et al:Sarcopenia phenotype and impaired muscle function in male mice with fast-twitch muscle-specific knockout of the androgen receptor. Proc Natl Acad Sci USA, 120:e2218032120, 2023(PMID:36669097)
10) Bonewald LF, et al:Forum on bone and skeletal muscle interactions:summary of the proceedings of an ASBMR workshop. J Bone Miner Res, 28:1857-1865, 2013[PMID:23671010]
11) Verschueren S, et al:Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int, 24:87-98, 2013[PMID:22776861]
12) Yoshimura N, et al:Is osteoporosis a predictor for future sarcopenia or vice versa? Four-year observations between the second and third ROAD study surveys. Osteoporos Int, 28:189-199, 2017[PMID:27885410]
13) Miyakoshi N, et al:Prevalence of sarcopenia in Japanese women with osteopenia and osteoporosis. J Bone Miner Metab, 31:556-561, 2013[PMID:23515924]
14) Oliveira A & Vaz C:The role of sarcopenia in the risk of osteoporotic hip fracture. Clin Rheumatol, 34:1673-1680, 2015[PMID:25912213]
15) Yoshimura N, et al:Do sarcopenia and/or osteoporosis increase the risk of frailty? A 4-year observation of the second and third ROAD study surveys. Osteoporos Int, 29:2181-2190, 2018[PMID:29931626]
16) Endo I, et al:Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology, 144:5138-5144, 2003[PMID:12959989]
17) Bischoff-Ferrari HA, et al:Effect of Vitamin D on falls:a meta-analysis. JAMA, 291:1999-2006, 2004[PMID:15113819]
P.239 掲載の参考文献
1) 「骨粗鬆症の予防と治療ガイドライン 2015年版」(骨粗鬆症の予防と治療ガイドライン作成委員会/編), ライフサイエンス出版, 2015
2) 厚生労働省:令和3年度地域保健・健康増進事業報告の概況. 2023 https://www.mhlw.go.jp/toukei/saikin/hw/c-hoken/21/index.html
3) 骨粗鬆症財団:骨粗鬆症検診率-検診者数及び各都道府県の検診受診率, 2020年https://www.jpof.or.jp/research/kenshin.html
4) Yoshimura N, et al:Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women:the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab, 27:620-628, 2009[PMID:19568689]
5) 森聖二郎:男性骨粗鬆症. 基礎老化研究, 34:13-17, 2010
6) Center JR, et al:Mortality after all major types of osteoporotic fracture in men and women:an observational study. Lancet, 353:878-882, 1999[PMID:10093980]
7) 厚生労働科学研究成果データベース:骨粗鬆症の予防及び検診提供体制の整備のための研究. https://mhlw-grants.niph.go.jp/project/156631
8) FRAX(R):骨折リスク評価ツール https://frax.shef.ac.uk/FRAX/tool.aspx?lang=jp
9) Chandran M, et al:Comparison of the Osteoporosis Self-Assessment Tool for Asians and the fracture risk assessment tool-FRAX to identify densitometric defined osteoporosis:A discriminatory value analysis in a multi-ethnic female population in Southeast Asia. Osteoporos Sarcopenia, 6:53-58, 2020[PMID:32715094]
10) Fan Z, et al:Comparison of OSTA, FRAX and BMI for Predicting Postmenopausal Osteoporosis in a Han Population in Beijing:A Cross Sectional Study. Clin Interv Aging, 15:1171-1180, 2020[PMID:32764904]
11) 山本憲男, 土屋弘行:FRAXを用いた新たな骨粗鬆症スクリーニング法の開発. 薬学雑誌, 139:35-38, 2019
12) Koh LK, et al:A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int, 12:699-705, 2001[PMID:11580084]
13) Fujiwara S, et al:Performance of osteoporosis risk indices in a Japanese population. Curr Ther Res, 62:586-594, 2001
14) Bhat KA, et al:Utility of Osteoporosis Self-Assessment Tool as a Screening Tool for Predicting Osteoporosis in Indian Men. J Clin Densitom, 20:160-163, 2017[PMID:27210803]
15) Zhang X, et al:Comparison of three tools for predicting primary osteoporosis in an elderly male population in Beijing:a cross-sectional study. Clin Interv Aging, 13:201-209, 2018[PMID:29440880]

最近チェックした商品履歴

Loading...